Adverse Events of Fluoxetine: Postmarketing Compared With Premarketing Clinical Trials
J Clin Psychiatry 2000;61:874 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: A prevalent perception exists among clinical pharmacologists and clinicians that the burden of adverse events is higher when a drug is utilized in the natural clinical environment than when used in premarketing clinical trials. The postmarketing study by Zajecka et al., which reported on the adverse events of fluoxetine, affords the opportunity to test this perception.